SEP 23, 2016 9:00 AM PDT

Access key technologies to accelerate genetic testing in your laboratory

Sponsored by: Natera, Natera
Speaker
  • Field Application Scientist Natera, Inc.
    Biography
      Samuel Suk received an M.S. in bioengineering from UCSD in La Jolla, California. Subsequently, he has held scientific support positions at Thermo Fisher and Fluidigm working with customers from a wide variety of industries. Currently, Samuel is a Field Application Scientist with Natera providing technical assistance worldwide to labs that are pursuing Panorama NIPT implementation.

    Abstract
    DATE: September 23, 2016
    TIME:   9:00 AM PST, 12:00 PM ET

     
    As genetic testing becomes more pervasive, many clinical and pathology laboratories see next generation sequencing (NGS) as an attractive evolution of their lab’s testing capabilities. There is already precedent for reimbursement by private and public insurers for genetic testing, particularly NGS genetic testing. However the decision to choose a genetic test that has a large market potential, is reimbursable (or willingly paid for out-of-pocket), and is easy to implement is daunting. One such test that meets all three business needs is the non-invasive prenatal test (NIPT). NIPT is applicable to a very large market (ca. 136.8M births per year globally). It is reimbursed by more private or government insurance and is readily paid for by consumers directly. The test is now easily implemented in most laboratories through Natera’s technology licensing program. Natera has invested 10s of millions of dollars in research and development and makes these technologies available to licensees under its technology licensing program. By licensing from Natera, laboratories can access some of the same technologies employed for Natera’s Panorama NIPT. This includes key Natera reagents, bioinformatics algorithms, and scientific resources used to develop a powerful NIPT offering. This webinar will introduce Natera’s technology licensing program and explain the process in which prospective licensee labs may license key Natera technology to perform NIPT in their own labs thereby offering a market leading NIPT in their own market.

    *Only available in certain geographies. Talk with your local representative for availability in your country*

     

    Show Resources
    You May Also Like
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    OCT 22, 2020 8:00 AM PDT
    C.E. CREDITS
    OCT 22, 2020 8:00 AM PDT
    Abstract: Detection and/or amplification of target DNA sequences by polymerase chain reaction (PCR) is a prevalent method in molecular biology. PCR has a broad range of applications, includi...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 02, 2020 7:00 AM PDT
    C.E. CREDITS
    SEP 02, 2020 7:00 AM PDT
    DATE: September 2, 2020 TIME: 03:00pm PDT, 6:00pm EDT Spatial omics is an expanding collection of methods to examine biological molecules in their geographical context. By retaining the prec...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    Loading Comments...
    Show Resources
    Attendees
    • See more